Comparison of Effectiveness and Side Effects of Combination of Memantine and Methylphenidate with Methylphenidate alone in Treatment of Children with Attention-Deficit/Hyperactivity Disorder

Document Type : Original Article


Department of Psychiatry, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.


Background and Objective: Attention deficit/Hyperactivity disorder (ADHD) is a common childhood psychiatric disorder and its early diagnosis and treatment have significant role in control of symptoms and prevention of the subsequent complications in children. This study assesses effects of combination of memantine and methylphenidate in treatment of children with ADHD.
Subjects and Methods:  This study was a double-blinded clinical trial. Thirty-six children with ADHD were divided randomly in two equal groups (18 in each group). The first group received a combination of methylphenidate and memantine and the second group received methylphenidate and placebo. The therapeutic effect was assessed by Conner’s scale and side effects were determined in each group at the begging and at the end of the first, second, third and fourth weeks after intervention.
Results: Conner’s test scores did not show statistically significant difference (P=0.835) between two groups at the beginning of study and at the end of the first week (P=0.136). However, at the end of the second, third and fourth weeks, the group of methylphenidate with memantine had more decline in Conner’s test scores (P=0.012, 0.001 and 0.002, repectivley) compared to group of methylphenidate with placebo. The overall results showed that the Conner’s scale decreased from 22.3 to 10 (P<0.001) in the methylphenidate and memantine combination group which was significantly lower than in methylphenidate with placebo (decreased from 22.4 to 13.5) (P<0.001). There was no statistically significant differences in side effects between two groups (P>0.05).
Conclusion: This study showed that methylphenidate with memantine is more effective than methylphenidate alone for ADHD in children and it has similar side effects profile.


1-Greenhill LL, Hechtman LI. Attention-Deficit/Hyperactivity Disorder. In: Sadock BJ, Sadock VA, Ruiz P. Comprehensive Text Book of Psychiatry. 9th ed. Philadelphia: Lippincott, Williams & Wilkins; 2009: 3560-72.
2-Sadock BG, Sadock VA . Kaplan and Sadock's Synopsis of psychiatry, behavioral clinical psychiatry.10th ed. Philadelphia (PA): Lippincott, Williams & Wilkins; 2007: 1044,1206-1217.
3-Hakim shooshtary M, Chimeh N, Najafi M, "et al". The   prevalence of attention deficit Hyperactivity disorder in Iran: A systematic review. Iran J Psychiatry 2010; 5: 88-92.
4-Tashakori A, Afkandeh R. prevalence of ADHD symptoms among male preschoolers based on different informants in Ahvaz city in Iran. ISRN Pediatrics 2011july;  2011: 1-4.
5-Wilens TE, Biederman J. ADHD across the life span. Annual reviews connect of medicine 2002 Feb; 53: 113-131.
6-Biederman J. Attention-deficit/hyperactivity disorder: A selective overview. Biol Psychiatry 2005; 57:1215–1220.
7-Kessler RC, Adler LA, Barkley R, Biederman J, Conners CK, Faraone SV, "et al". Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication. Biol Psychiatry 2005; 57: 1442–1451.
8-Carrey N, MacMaster FP, Fogel J, Sparkes S, Waschbusch D, Sullivan S, "et al". Metabolite changes resulting from treatment in children with ADHD: A 1H-MRS study. Clin Neuropharmacol 2003July-agust; 26(4): 218–221.
9-Riahi F, Tashakori A, Izadi-Mazidi S, Salehi-Veisi M. Effectiveness of reboxetine in treatment of outpatient children and adolescents with attention deficit/ hyperactivity disorder with comorbid anxiety disorders. Iran J Psychiatry 2013; 8(4): 195-200.
10-Russell VA. Increased AMPA receptor function in slices containing the prefrontal cortex of spontaneously hypertensive rats. Metab Brain Dis 2001 Dec; 16(3,4): 143–149.
11-Kotecha SA, Oak JN, Jackson MF, Perez Y, Orser BA, Van Tol HH,: AD2 class dopamine receptor transactivates a receptor tyrosine kinase to inhibit NMDA receptor transmission. Neuron 2002 Sep; 35(6): 1111-1122.
12-Winblad B, Poritis N. Memantine in severe dementia: results of the M-BEST Study (Benefit andefficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999; 14: 135–146.
13-Forest Laboratories: Data on file. New York: Forest Laboratories, Inc; 2005.
14-Findling RL,McNamark Nk. A pilot evaluation of the safety ,tolerability,pharmacokinetics and effectiveness in pediatric patients with attention-deficit/hyperactivity disorder combined type. J child   adolesc psychopharmacol 2007; 17(1): 19-33.
15-Erickson F. A retrospective study of memantine in children and adolescents with PDD, psychopharmacology 2007; 191: 141-147.
16-Mohammadzadeh S, Mohammadi MR, Akhondzadeh S. comparison of memantine and ritalin in the treatment of children with ADHD. Proceeding of the Iranian 6th International congress of child and adolescent psychiatry; 2013 Sep 17-19; Iran: Tabriz; 2013. P. 171.
17-Weiss M, Weiss G. Attention Deficit- Hyperactivity Disorder. In: Martin A, Volkmar FR. Lewis's Child and Adolescent Psychiatry: A Comprehensive Textbook. 3rd ed. Philadelphia (PA): Lippincott, Williams & Wilkins; 2002, P: 645-51.
18-Brock SE, Clinton A. Diagnosis of attention deficit/ hyperactivity disorder (AD/HD) in childhood: A review of the literature. J child Dev 2007; (12):73-91.
19-Shhayyan A,؛ Shahim TV, Beaming Laya, Yousefi Farida. Normalization, Factor analysis and reliability of the short form of special Conners Parent Rating Scale for children 6 to 11 years in Shiraz city. Journal of Psychological Studies 2007 Fall; 3(3): 97-120.
20-Jann MW, Small GW. Cholinesterase inhibitors. In: Sadock BJ, Sadock VA, Ruiz P. Comprehensive Text Book of Psychiatry. 9th ed. Philadelphia: Lippincott, Williams & Wilkins; 2009: 3096-7.